INOVIO PHARMACEUTICALS, INC. (INO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 9M 18M 27M Q1 '10: 1.4M Q2 '10: 1.1M Q3 '10: 1.3M Q4 '10: 2.4M Q1 '11: 3.1M Q2 '11: 2.4M Q3 '11: 2.6M Q4 '11: 1.6M Q1 '12: 1.7M Q2 '12: 436.1K Q3 '12: 854.7K Q4 '12: 1.1M Q1 '13: 1.5M Q2 '13: 785.6K Q3 '13: 9.5M Q4 '13: 1.7M Q1 '14: 2.4M Q2 '14: 3.8M Q3 '14: 1.8M Q4 '14: 2.5M Q1 '15: 5.2M Q2 '15: 5.3M Q3 '15: 24.2M Q4 '15: 5.9M Q1 '16: 8.1M Q2 '16: 6.2M Q3 '16: 12.5M Q4 '16: 8.5M Q1 '17: 10.4M Q2 '17: 20.4M Q3 '17: 2.6M Q4 '17: 8.8M Q1 '18: 1.5M Q2 '18: 24.4M Q3 '18: 2M Q4 '18: 2.5M Q1 '19: 2.8M Q2 '19: 135.7K Q3 '19: 866.9K Q4 '19: 279.5K Q1 '20: 1.3M Q2 '20: 267.2K Q3 '20: 236.2K Q4 '20: 5.6M Q1 '21: 371.1K Q2 '21: 272.8K Q3 '21: 291.7K Q4 '21: 839.1K Q1 '22: 199.1K Q2 '22: 784.4K Q3 '22: 9.2M Q4 '22: 124.7K Q1 '23: 114.9K Q2 '23: 226K Q3 '23: 388.4K Q4 '23: 102.7K Q1 '24: 0 Q2 '24: 100.8K Q3 '24: 0 Q4 '24: 117K Q1 '25: 65.3K Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q3 '10 Q4 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-120M -80M -40M 0 40M 80M 120M Q1 '10: -4.4M Q2 '10: -5M Q3 '10: -4.6M Q4 '10: -5.3M Q1 '11: -4.4M Q2 '11: -5.1M Q3 '11: -6.3M Q4 '11: -5.8M Q1 '12: -4.2M Q2 '12: -6.8M Q3 '12: -6.3M Q4 '12: -6.2M Q1 '13: -6.6M Q2 '13: -5.7M Q3 '13: 765.6K Q4 '13: -8M Q1 '14: -10M Q2 '14: -10.2M Q3 '14: -8.3M Q4 '14: -11M Q1 '15: -8.4M Q2 '15: -15.1M Q3 '15: 3.7M Q4 '15: -14.5M Q1 '16: -15.5M Q2 '16: -18.2M Q3 '16: -20.2M Q4 '16: -22.4M Q1 '17: -21.9M Q2 '17: -9.6M Q3 '17: -29.2M Q4 '17: -22.9M Q1 '18: -32.7M Q2 '18: -5.2M Q3 '18: -26.6M Q4 '18: -29.5M Q1 '19: -28.5M Q2 '19: -28.2M Q3 '19: -24M Q4 '19: -30.4M Q1 '20: -25.2M Q2 '20: -33.2M Q3 '20: -36.3M Q4 '20: -29.3M Q1 '21: -52.6M Q2 '21: -83.2M Q3 '21: -60M Q4 '21: -105.5M Q1 '22: -71.7M Q2 '22: -104.1M Q3 '22: -35.8M Q4 '22: -55.9M Q1 '23: -44M Q2 '23: -37M Q3 '23: -35.6M Q4 '23: -27.4M Q1 '24: -31.5M Q2 '24: -33.2M Q3 '24: -27.3M Q4 '24: -20.4M Q1 '25: -25.1M Q2 '25: -23.1M Q3 '25: -21.2M Q4 '25: -17.5M Q1 '26: -21.9M Q2 '26: -18.6M Q3 '10 Q4 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Net Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q1 '10: -2.3M Q2 '10: -7.6M Q3 '10: -1.4M Q4 '10: -6.3M Q1 '11: -2.4M Q2 '11: -2.8M Q3 '11: -4.5M Q4 '11: -5.5M Q1 '12: -8.3M Q2 '12: -4.1M Q3 '12: -6.6M Q4 '12: -658.8K Q1 '13: -8.8M Q2 '13: -10.9M Q3 '13: -30.9M Q4 '13: -15.5M Q1 '14: -10.8M Q2 '14: -10.7M Q3 '14: -7.2M Q4 '14: -7.4M Q1 '15: -10.6M Q2 '15: -6.2M Q3 '15: 5.6M Q4 '15: -18M Q1 '16: -8M Q2 '16: -18.7M Q3 '16: -20.8M Q4 '16: -26.2M Q1 '17: -23.1M Q2 '17: -9.5M Q3 '17: -34.1M Q4 '17: -21.5M Q1 '18: -32.4M Q2 '18: -6.6M Q3 '18: -25M Q4 '18: -33M Q1 '19: -29.2M Q2 '19: -29.4M Q3 '19: -23.1M Q4 '19: -37.7M Q1 '20: -32.5M Q2 '20: -128.7M Q3 '20: 19.2M Q4 '20: -24.3M Q1 '21: -54.4M Q2 '21: -82.1M Q3 '21: -60.2M Q4 '21: -106.9M Q1 '22: -79.1M Q2 '22: -108.5M Q3 '22: -37.8M Q4 '22: -54.5M Q1 '23: -40.6M Q2 '23: -35.5M Q3 '23: -33.9M Q4 '23: -25M Q1 '24: -30.5M Q2 '24: -32.2M Q3 '24: -25.2M Q4 '24: -19.4M Q1 '25: -19.7M Q2 '25: -23.5M Q3 '25: -45.5M Q4 '25: 3.8M Q1 '26: -19.7M Q2 '26: -6M Q3 '10 Q4 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '10: -783.7K Q4 '10: -3.3M Q1 '11: -5.5M Q2 '11: -4.5M Q3 '11: -5.3M Q4 '11: -4.5M Q1 '12: -5.4M Q2 '12: -5.3M Q3 '12: -6M Q4 '12: -5.5M Q1 '13: -5.1M Q2 '13: -5.4M Q3 '13: -5.7M Q4 '13: 874.9K Q1 '14: -5.6M Q2 '14: -8.1M Q3 '14: -8M Q4 '14: -8.1M Q1 '15: -12.1M Q2 '15: -9M Q3 '15: 15.4M Q4 '15: -6.8M Q1 '16: -15.7M Q2 '16: -13.3M Q3 '16: -18.6M Q4 '16: -14.9M Q1 '17: -15.2M Q2 '17: -16.7M Q3 '17: -17.3M Q4 '17: -13.9M Q1 '18: -12.6M Q2 '18: -19M Q3 '18: -24.7M Q4 '18: -17.3M Q1 '19: -32.5M Q2 '19: -23.9M Q3 '19: -27.7M Q4 '19: -13.7M Q1 '20: -25.5M Q2 '20: -27.2M Q3 '20: -74.2M Q4 '20: -51.2M Q1 '21: -52.9M Q2 '21: -78.5M Q3 '21: -46.5M Q4 '21: -37.9M Q1 '22: -61.9M Q2 '22: -50.5M Q3 '22: -67.5M Q4 '22: -36.3M Q1 '23: -36.7M Q2 '23: -32.3M Q3 '23: -29.1M Q4 '23: -26.3M Q1 '24: -28.8M Q2 '24: -28.2M Q3 '24: -27.4M Q4 '24: -19.7M Q1 '25: -26.9M Q2 '25: -20.8M Q3 '25: -21.6M Q4 '25: -19.4M Q1 '26: -21.6M Q2 '26: -18M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '10: -807.7K Q4 '10: -3.4M Q1 '11: -5.6M Q2 '11: -4.5M Q3 '11: -5.3M Q4 '11: -4.6M Q1 '12: -5.5M Q2 '12: -5.4M Q3 '12: -6.1M Q4 '12: -5.5M Q1 '13: -5.2M Q2 '13: -5.4M Q3 '13: -5.9M Q1 '14: -5.7M Q2 '14: -8.9M Q3 '14: -8.4M Q4 '14: -8.2M Q1 '15: -12.6M Q2 '15: -9.7M Q3 '15: 14.6M Q4 '15: -7.6M Q1 '16: -16.4M Q2 '16: -14.8M Q3 '16: -19.1M Q4 '16: -15M Q1 '17: -16M Q2 '17: -21.8M Q3 '17: -20.9M Q4 '17: -14.8M Q1 '18: -13.7M Q2 '18: -19.5M Q3 '18: -24.8M Q4 '18: -17.6M Q1 '19: -33.1M Q2 '19: -24M Q3 '19: -27.9M Q4 '19: -13.9M Q1 '20: -25.6M Q2 '20: -27.2M Q3 '20: -74.5M Q4 '20: -52.2M Q1 '21: -53.1M Q2 '21: -78.7M Q3 '21: -46.7M Q4 '21: -38.5M Q1 '22: -61.9M Q2 '22: -51.2M Q3 '22: -67.6M Q4 '22: -36.5M Q1 '23: -37M Q2 '23: -32.3M Q3 '23: -29.1M Q4 '23: -26.3M Q1 '24: -28.8M Q2 '24: -28.7M Q3 '24: -27.4M Q4 '24: -19.7M Q1 '25: -26.9M Q2 '25: -20.8M Q3 '25: -21.6M Q4 '25: -19.5M Q1 '26: -21.6M Q2 '26: -18M Q1 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 90M 180M 270M Q1 '13: 39M Q2 '13: 45M Q3 '13: 48M Q4 '13: 52.1M Q1 '14: 55.2M Q2 '14: 60.5M Q3 '14: 60.6M Q4 '14: 60.8M Q1 '15: 60.9M Q2 '15: 67.8M Q3 '15: 74M Q4 '15: 72.2M Q1 '16: 72.2M Q2 '16: 73M Q3 '16: 73.8M Q1 '17: 74.3M Q2 '17: 75.4M Q3 '17: 87.1M Q1 '18: 90.5M Q2 '18: 91.2M Q3 '18: 92.4M Q2 '19: 98.1M Q3 '19: 102.8M Q2 '20: 155.8M Q3 '20: 174.4M Q1 '21: 202.4M Q2 '21: 209.6M Q3 '21: 210.3M Q1 '22: 218.9M Q2 '22: 235.3M Q3 '22: 249.4M Q1 '23: 21.5M Q2 '23: 22M Q3 '23: 22.4M Q1 '24: 23.3M Q2 '24: 27.2M Q3 '24: 28.1M Q1 '25: 38.6M Q2 '25: 38.8M Q3 '25: 52.2M Q1 '26: 69.1M Q2 '26: 81.6M Q2 '14 Q4 '15 Q3 '17 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-21.00 -14.00 -7.00 0.00 7.00 14.00 21.00 Q4 '10: -0.17 Q1 '11: -0.16 Q2 '11: -0.11 Q3 '11: -0.14 Q4 '11: -0.12 Q1 '12: -0.16 Q2 '12: -0.17 Q3 '12: -0.18 Q4 '12: -0.14 Q1 '13: -0.31 Q2 '13: -0.52 Q3 '13: -1.11 Q4 '13: -1.41 Q1 '14: -1.38 Q2 '14: -1.33 Q3 '14: -0.81 Q4 '14: -0.63 Q1 '15: -0.61 Q2 '15: -0.51 Q3 '15: -0.32 Q4 '15: -0.45 Q1 '16: -0.38 Q2 '16: -0.55 Q3 '16: -0.90 Q4 '16: -1.01 Q1 '17: -1.21 Q2 '17: -1.08 Q3 '17: -1.20 Q4 '17: -1.08 Q1 '18: -1.13 Q2 '18: -1.08 Q3 '18: -0.95 Q4 '18: -1.05 Q1 '19: -0.99 Q2 '19: -1.21 Q3 '19: -1.19 Q4 '19: -1.23 Q1 '20: -1.19 Q2 '20: -1.72 Q3 '20: -1.36 Q4 '20: -1.12 Q1 '21: -1.13 Q2 '21: -0.69 Q3 '21: -1.09 Q4 '21: -17.45 Q1 '22: -17.54 Q2 '22: -17.61 Q3 '22: -17.47 Q4 '22: -14.08 Q1 '23: -15.61 Q2 '23: -16.76 Q3 '23: -18.13 Q4 '23: -6.10 Q1 '24: -5.52 Q2 '24: -5.10 Q3 '24: -4.47 Q4 '24: -3.99 Q1 '25: -3.19 Q2 '25: -2.61 Q3 '25: -2.59 Q4 '25: -1.81 Q1 '26: -1.58 Q2 '26: -1.04 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.